| 1 | How to manage Pseudomonas aeruginosa infections (10.7573/dic.212527) | Abstract References ORCID License | 278.25 | 605 |
| 2 | A clinical review of GLP-1 receptor agonists: efficacy and s… (10.7573/dic.212283) | Abstract References ORCID License | 248.29 | 303 |
| 3 | Comorbidity in social anxiety disorder: diagnostic and thera… (10.7573/dic.212573) | Abstract References ORCID License | 224.80 | 176 |
| 4 | Aducanumab: evidence from clinical trial data and controvers… (10.7573/dic.2021-7-3) | Abstract References ORCID License | 222.01 | 165 |
| 5 | Antidepressant efficacy and side-effect burden: a quick guid… (10.7573/dic.212290) | Abstract References ORCID License | 221.48 | 163 |
| 6 | Febrile seizures: an overview (10.7573/dic.212536) | Abstract References ORCID License | 221.48 | 163 |
| 7 | High-density lipoprotein (HDL) functionality and its relevan… (10.7573/dic.212525) | Abstract References ORCID License | 220.68 | 160 |
| 8 | Combination therapy in the treatment of hypertension (10.7573/dic.212531) | Abstract References ORCID License | 216.14 | 144 |
| 9 | The role of anti-vascular endothelial growth factor (anti-VE… (10.7573/dic.212532) | Abstract References ORCID License | 215.53 | 142 |
| 10 | Dermatology: how to manage acne vulgaris (10.7573/dic.2021-8-6) | Abstract References ORCID License | 211.39 | 129 |
| 11 | The journey of remdesivir: from Ebola to COVID-19 (10.7573/dic.2020-4-14) | Abstract References ORCID License | 210.72 | 127 |
| 12 | Menopause hormone therapy: latest developments and clinical… (10.7573/dic.212551) | Abstract References ORCID License | 207.19 | 117 |
| 13 | Advances in the use of PARP inhibitor therapy for breast can… (10.7573/dic.212540) | Abstract References ORCID License | 205.31 | 112 |
| 14 | New developments in ulcerative colitis: latest evidence on m… (10.7573/dic.212572) | Abstract References ORCID License | 205.31 | 112 |
| 15 | Ketamine as treatment for post-traumatic stress disorder: a… (10.7573/dic.212305) | Abstract References ORCID License | 197.77 | 94 |
| 16 | The race to a COVID-19 vaccine: opportunities and challenges… (10.7573/dic.2020-12-2) | Abstract References ORCID License | 196.85 | 92 |
| 17 | Emerging systemic JAK inhibitors in the treatment of atopic… (10.7573/dic.2020-8-5) | Abstract References ORCID License | 195.42 | 89 |
| 18 | Venetoclax: evidence to date and clinical potential (10.7573/dic.212574) | Abstract References ORCID License | 195.42 | 89 |
| 19 | Palbociclib in metastatic breast cancer: current evidence an… (10.7573/dic.212579) | Abstract References ORCID License | 194.94 | 88 |
| 20 | The therapeutic role of minocycline in Parkinson’s disease (10.7573/dic.212553) | Abstract References ORCID License | 193.45 | 85 |
| 21 | Motion sickness: an overview (10.7573/dic.2019-9-4) | Abstract References ORCID License | 191.91 | 82 |
| 22 | One-year prevalence, comorbidities and cost of cachexia-rela… (10.7573/dic.212265) | Abstract References ORCID License | 191.38 | 81 |
| 23 | Neurological features of COVID-19 and their treatment: a rev… (10.7573/dic.2020-5-1) | Abstract References ORCID License | 187.51 | 74 |
| 24 | Brodalumab in psoriasis: evidence to date and clinical poten… (10.7573/dic.212570) | Abstract References ORCID License | 185.13 | 70 |
| 25 | Urinary tract infections in the elderly: a review of disease… (10.7573/dic.2020-4-13) | Abstract References ORCID License | 184.51 | 69 |
| 26 | Emollient treatment of atopic dermatitis: latest evidence an… (10.7573/dic.212530) | Abstract References ORCID License | 183.88 | 68 |
| 27 | Tinea corporis: an updated review (10.7573/dic.2020-5-6) | Abstract References ORCID License | 183.25 | 67 |
| 28 | Adding ezetimibe to statin therapy: latest evidence and clin… (10.7573/dic.212534) | Abstract References ORCID License | 183.25 | 67 |
| 29 | Immunotherapy in renal cell carcinoma: latest evidence and c… (10.7573/dic.212528) | Abstract References ORCID License | 182.61 | 66 |
| 30 | Upadacitinib and filgotinib: the role of JAK1 selective inhi… (10.7573/dic.212595) | Abstract References ORCID License | 181.29 | 64 |
| 31 | Topical treatment of radiation-induced dermatitis: current i… (10.7573/dic.2020-4-7) | Abstract References ORCID License | 179.93 | 62 |
| 32 | Xeroderma pigmentosum: an updated review (10.7573/dic.2022-2-5) | Abstract References ORCID License | 179.93 | 62 |
| 33 | Diagnosis and management of lentigo maligna: a review (10.7573/dic.212281) | Abstract References ORCID License | 179.24 | 61 |
| 34 | A review of current treatment strategies for gestational dia… (10.7573/dic.212282) | Abstract References ORCID License | 179.24 | 61 |
| 35 | Tinea versicolor: an updated review (10.7573/dic.2022-9-2) | Abstract References ORCID License | 175.59 | 56 |
| 36 | The cost of biologics for psoriasis is increasing (10.7573/dic.212266) | Abstract References ORCID License | 175.59 | 56 |
| 37 | Inflammatory bowel disease in patients with psoriasis treate… (10.7573/dic.2020-2-1) | Abstract References ORCID License | 174.82 | 55 |
| 38 | Neonatal pharmacology and clinical implications (10.7573/dic.212608) | Abstract References ORCID License | 174.82 | 55 |
| 39 | Metformin in the management of diabetes during pregnancy and… (10.7573/dic.212523) | Abstract References ORCID License | 174.04 | 54 |
| 40 | Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growin… (10.7573/dic.212264) | Abstract References ORCID License | 173.24 | 53 |
| 41 | Gastroesophageal reflux in children: an updated review (10.7573/dic.212591) | Abstract References ORCID License | 173.24 | 53 |
| 42 | Dermatology: how to manage facial hyperpigmentation in skin… (10.7573/dic.2021-11-2) | Abstract References ORCID License | 172.43 | 52 |
| 43 | Atopic dermatitis: a review of topical nonsteroid therapy (10.7573/dic.212521) | Abstract References ORCID License | 172.43 | 52 |
| 44 | Alpha-2 receptor agonists for the treatment of posttraumatic… (10.7573/dic.212286) | Abstract References ORCID License | 168.12 | 47 |
| 45 | Current treatment in COVID-19 disease: a rapid review (10.7573/dic.2020-10-3) | Abstract References ORCID License | 167.21 | 46 |
| 46 | Cardiac myosin activators for heart failure therapy: focus o… (10.7573/dic.212518) | Abstract References ORCID License | 166.28 | 45 |
| 47 | Medication adherence and treatment-resistant hypertension: a… (10.7573/dic.212560) | Abstract References ORCID License | 165.32 | 44 |
| 48 | Guselkumab for the treatment of psoriasis – evidence to date (10.7573/dic.212594) | Abstract References ORCID License | 165.32 | 44 |
| 49 | Tofacitinib and newer JAK inhibitors in inflammatory bowel d… (10.7573/dic.2021-11-4) | Abstract References ORCID License | 163.35 | 42 |
| 50 | Tinea pedis: an updated review (10.7573/dic.2023-5-1) | Abstract References ORCID License | 162.32 | 41 |